These three proteins (Figure 1) are the targets of most immunotherapeutic agents developed to date [19] and, as referred to above, daratumumab, targeted against CD38, is already part of the current standard-of-care first-line treatment of AL amyloidosis, in combination with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) [25]. This evidence concerns the gene CD38 and AL amyloidosis.